Announcement.

PHARMENA SA (28/2018) Monthly report for October 2018

The Management Board of Pharmena S.A. forwards the monthly report for October 2018. & lt; br / & gt; 1. Description of tendencies and events in the Issuer's environment & lt; br / & gt; According to the Management Board, in October 2018, in the Issuer's environment, there were no phenomena or trends that could have a significant impact on the company's financial results. & Lt; br / & gt; During the period in question, Pharmena S.A. broadened the availability of products and undertook marketing activities to increase the revenue from the sale of products offered. & Lt; br / & gt; The Management Board of PHARMENA S.A. (hereinafter: the "Company") informed that on October 12, 2018, the application for approval of the Company's prospectus was submitted to the Polish Financial Supervision Authority. The prospectus was prepared in connection with the intention to apply for admission and introduction to the regulated market on the Warsaw Stock Exchange SA: & lt; br / & gt; • 5,730,000 Series A shares with a nominal value of PLN 0.10 each, & lt; br / & gt; • 522,260 series B shares with a nominal value of PLN 0.10 each, & lt; br / & gt; • 781.782 Series C shares with a nominal value of PLN 0.10 each & lt; br / & gt; • 1,759,010 series D shares with a nominal value of PLN 0.10 each, & lt; br / & gt; • 2,638,516 series E shares with a nominal value of PLN 0.10 each & lt; br / & gt; • 2.638.516 Rights to Series E Shares ("PDAs") and & lt; br / & gt; • 2.638.516 Share Rights of the series E. & lt; br / & gt; In addition, in September 2018, the Issuer's Capital Group continued its research and development work on new products and the search for new applications of active substances protected by patents and patent applications belonging to the Issuer's Capital Group. & Lt; br / & gt; 2. Realization of emission goals & lt; br / & gt; The Issuer's Capital Group fulfilled the issue objectives expending for their implementation all cash obtained from the issue of series C and D shares. Therefore, in the period covered by the report, it did not spend funds for issue purposes. & Lt; br / & gt; 3. Summary of reports published by the Issuer in the period from 01/10/2018 to 31/10/2018 & lt; br / & gt; In the period covered by this report, Pharmena S.A. published the following reports in the EBI system: & lt; br / & gt; • Current report No. 26/2018 of 12/10/2018 - Monthly report for September 2018 & lt; br / & gt; • Current report No. 27/2018 of 12/10/2018 - Submission of an application for approval of a prospectus toPolish Financial Supervision Authority & lt; br / & gt; In the period covered by this report, Pharmena S.A. did not publish reports in the ESPI system. & Lt; br / & gt; 4. The investor's calendar for November 2018 & lt; br / & gt; • 13/11/2018 - publication of the report for the third quarter of 2018. & lt; br / & gt; • Until 14/12/2018 - publication of the monthly report for November 2018 & lt; br / & gt; Legal basis: point 16 of Annex No. 1 to Resolution No. 795/2008 of the Exchange Management Board of November 31, 2008 - "Good Practices of NewConnect Listed Companies". & Lt; br / & gt; Persons representing the company: & lt; br / & gt; Konrad Palka - President of the Board & lt; br / & gt; Marzena Wieczorkowska - Vice President of the Board & lt; br / & gt;

Source: company website, investor relations, current and periodic reports.

ALL COMPANY ANNOUNCMENTS
Company information
Company name:Pharmena SA
ISIN:PLPHRMN00011
NIP:728-24-67-846
Adress: ul. Wólczańska 178 90-530 Łódź
Phone:+48 42 2913370
website:www.pharmena.com.pl

Copyright © 2017 PolandStockExchange
This website uses cookies (Regulations / Cookie Policy).